SCHEMBL4616465

SCHEMBL4616465

CC(C)c1ccc(S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
MAPT P10636 2/20 0.61
LMNA P02545 2/20 0.61
KDM4E B2RXH2 1/20 0.61
GAA P10253 1/20 0.61
HTR6 P50406 2/20 0.61
CHRM2 P08172 6/20 0.56
CHRM1 P11229 6/20 0.56
CNR2 P34972 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
POLB P06746 2/20 0.47
PKM P14618 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
MEN1 O00255 1/20 0.44
NSD2 O96028 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
HSD11B1 P28845 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11850699 0.91 LMNA (0.70) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL879249 0.87 CNR2 (0.47) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL24589993 0.83 HTR6 (0.56) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL31060472 0.83 HTR6 (0.56) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL11872140 0.83 GAA (0.70) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL11117363 0.83 LMNA (0.70) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL13272458 0.83 ALDH1A1 (0.70) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL8046879 0.82 GAA (0.58) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL23974988 0.82 CNR2 (0.42) ALDH1A1MAPTLMNAKDM4EGAA
SCHEMBL10179635 0.82 HTR6 (0.54) ALDH1A1MAPTLMNAKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101208299-A Diarylsulfone sulfonamides and use therof WYETH CORP (US) 2008-06-25 CN claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
US-20230174506-A1 (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME PURDUE RESEARCH FOUNDATION 2023-06-08 US disclosed
WO-2021099447-A1 POLYMERS, COMPOSITIONS AND METHOD FOR MANUFACTURING AN ARTICLE BY 3D PRINTING SOLVAY SPECIALTY POLYMERS USA, LLC (US) 2021-05-27 WO disclosed
US-10472564-B2 Delayed fluorescence compound and organic electroluminescent device using the same LUMINESCENCE TECHNOLOGY CORP. (TW) 2019-11-12 US disclosed
US-20190093009-A1 DELAYED FLUORESCENCE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-03-28 US disclosed
US-20170244034-A1 AROMATIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME NATIONAL TSING HUA UNIVERSITY (TW) 2017-08-24 US disclosed
US-20170244034-A1 AROMATIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME NATIONAL TSING HUA UNIVERSITY (TW) 2017-08-24 US disclosed
US-9187459-B2 Quinazoline-7-ether compounds and methods of use NEWGEN THERAPEUTICS, INC. (US) 2015-11-17 US disclosed
US-20140221406-A1 QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE NEWGEN THERAPEUTICS, INC. (US) 2014-08-07 US disclosed
US-7696210-B2 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2010-04-13 US disclosed
US-7696210-B2 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2010-04-13 US disclosed
US-20090170845-A1 USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN AEGERA THERAPEUTICS INC. (CA) 2009-07-02 US disclosed
US-20090170845-A1 USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN AEGERA THERAPEUTICS INC. (CA) 2009-07-02 US disclosed
CN-101208299-A Diarylsulfone sulfonamides and use therof WYETH CORP (US) 2008-06-25 CN disclosed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170845-A1 USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN SCN1B, SCN3A, SCN1A ALDH1A1 658/4885MAPT 2535/4885LMNA 4033/4885
US-20230174506-A1 (DI)AMINATION OF ACTIVATED ALLENE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR SYNTHESIS OF THE SAME NAAA, PAM, AANAT ALDH1A1 583/4885MAPT 3692/4885LMNA 1994/4885
US-20170244034-A1 AROMATIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME ARNT, AHR, CYP1A1 ALDH1A1 11/4885MAPT 748/4885LMNA 3515/4885
US-10472564-B2 Delayed fluorescence compound and organic electroluminescent device using the same SLCO4C1, LEF1, SLCO2A1 ALDH1A1 2768/4885MAPT 926/4885LMNA 1633/4885
US-20140221406-A1 QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE ABL1, ERBB4, ERBB2 ALDH1A1 3808/4885MAPT 3552/4885LMNA 2534/4885
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 ALDH1A1 1865/4885MAPT 4680/4885LMNA 4608/4885
US-20190093009-A1 DELAYED FLUORESCENCE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME SLCO4C1, LEF1, SLCO2A1 ALDH1A1 2768/4885MAPT 926/4885LMNA 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.